Qureight announces its Scientific Advisory Board for Idiopathic Pulmonary Fibrosis (IPF)
Posted on: 23 Aug 22
Qureight today announces its Scientific Advisory Board for Idiopathic Pulmonary Fibrosis (IPF). This progressive scarring lung disease is one of the company’s three benchmark conditions alongside Pulmonary Arterial Hypertension and Non-small cell lung cancer. IPF is a complex disease which is difficult to diagnose and monitor. The Qureight platform has recently been successfully used as a surrogate clinical trial endpoint by analysing and structuring complex data from a phase 2 IPF study (results to be announced at European Respiratory Society meeting in Barcelona on 5th September 2022). Qureight’s platform for IPF and other progressive fibrosing interstitial lung diseases (ILDs) is being rapidly adopted for accelerating clinical trials and developing new and clearer clinical endpoints in these complex diseases.
As the platform becomes more widely used with biopharma partners worldwide, the company has formed this Scientific Advisory Board with leading experts in the field of clinical trial and drug development. CEO Dr. Muhunthan Thillai said: “The bringing together of global IPF experts provides a clear signal that the Qureight platform technology is able to support development of new drugs for IPF. These experts have amongst them been responsible for delivering the current generation of antifibrotic medications and are key leaders in development for the next set of medications with some of our global biopharma partners. We look forward to working with them and shortly adopting our models for data curation in our next set of complex diseases.”